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Summary 
 
 Necdin is a pleiotropic protein that promotes differentiation and survival of 
mammalian neurons.  Necdin is expressed abundantly in postmitotic neurons and 
interacts with many nuclear proteins such as E2F family proteins, p53, 
hypoxia-inducible proteins, Bmi-1, Sirtuin1, and FoxO1.  Necdin is a member of 
MAGE (melanoma antigen) family proteins that share a highly conserved MAGE 
homology domain.  It has previously been reported that several MAGE proteins 
interact with ubiquitin E3 ligases and modulate their activities.  However, it remains 
unknown whether necdin and its related MAGE family proteins interact with SUMO 
(small ubiquitin-like modifier) E3 ligases such as PIAS (Protein Inhibitor of Activated 
STAT) family, Nsmce2/Mms21 and Cbx4/Pc2.  In the present study, we investigated 
whether necdin interacts with these SUMO E3 ligases. 
 We first examined whether necdin and other MAGE proteins (necdin-like 2, 
MAGED1, MAGEF1, MAGEL2) interact with three known SUMO E3 ligases PIAS1, 
Nsmce2, and Cbx4.  Co-immunoprecipitation analysis revealed that necdin, 
MAGED1, MAGEF1 and MAGEL2 bound to PIAS1 but not to Nsmce2 or Cbx4.  
These SUMO E3 ligases bound to MAGEA1 but failed to interact with necdin-like 2 
(MAGEG1).  Necdin bound via its hydrophobic pocket domain to PIAS1 central 
domains including PINIT (Pro-Ile-Asn-Ile-Thr)-motif and RING (Really Interesting 
New Gene) domains, which are highly conserved among PIAS family proteins and 
indispensable for the catalytic activity.  We then examined the effects of necdin on 
the SUMOylation activity of PIAS1.  Necdin suppressed PIAS1-dependent 
SUMOylation of the substrates STAT1 and PML (promyelocytic leukemia protein). 
Moreover, necdin strongly suppressed the effects of PIAS1 on the transcriptional 
activities of p53 and PML.  In co-transfection assays, PIAS1 protein levels were 
markedly reduced by co-expressed necdin, and the reduction of PIAS1 levels was 
relieved in the presence of the proteasome inhibitor MG132. Furthermore, necdin 
markedly promoted degradation of PIAS1 via the ubiquitin-proteasome pathway.  In 
transfected HEK293A cells, N- and C-terminally truncated PIAS1 mutants bound to 
necdin but failed to undergo necdin-dependent ubiquitination, indicating that the N- 
and C-terminal domains intramolecularly regulate ubiquitination. Because the 
N-terminus of PIAS1 contains the SAP (SAF-Acinus-PIAS) domain that interacts with 
the nuclear matrix, we examined whether N- and C-terminal deletions of PIAS1 affect 
its association with the nuclear matrix.  Both PIAS1 and necdin were associated with 
the nuclear matrix, to which the PIAS1 terminal deletion mutants failed to localize, 
implying that the nuclear matrix is indispensable for necdin-dependent ubiquitination 
of PIAS1. Furthermore, lentivirus-mediated necdin overexpression in H1299 cells 
reduced endogenous PIAS1 protein levels and decreased proliferation rates. 
 The present study has demonstrated that necdin suppresses the function of PIAS1 
both by inhibiting its SUMO E3 ligase activity and by promoting ubiquitin-dependent 
degradation.  Protein SUMOylation levels are high in neural stem cells, in which 
PIAS1 expression is upregulated.  Expression of necdin is low in neural 
stem/progenitor cells and upregulated during neuronal differentiation.  These findings 
suggest that necdin suppresses SUMOylation of PIAS1 substrate proteins involved in 
neuronal differentiation.  The present study also provides insights into the 
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involvement of necdin and other MAGE family proteins in PIAS1-mediated events in 
various types of cells.  
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I.  INTRODUCTION 
I-1.  General introduction  
I-1.1. Posttranslational modifications with ubiquitin and SUMO 
 Protein posttranslational modifications include the covalent addition of small 
chemical groups or proteins, proteolytic cleavage, and degradation of entire proteins. 
These modifications influence almost all aspects of cellular events under physiological 
and pathological conditions. 
 Ubiquitin was first discovered in 1975, as a highly enriched protein in thymic 
fractions (Goldstein, 1975). Ubiquitin mainly targets the conjugated proteins to 
proteasomal proteolysis.  Several other ubiquitin-like small proteins (UBLs) have 
been found later to act as mediators of post-translational modifications. These proteins 
are collectively called ubiquitin-like proteins (UBLs), which include SUMO (small 
ubiquitin-related modifier), Nedd8, ISG15, Atg8, URM1, FAT10 and MNSFβ (van der 
Veen and Ploegh, 2012).  Unlike ubiquitin, UBLs mediate a wide array of distinct 
functions of conjugated proteins.   
 Lys residues are most frequently modified with ubiquitin.  There has been no 
consensus sequence motif for ubiquitination (Finley and Chau, 1991), whereas UBL 
modification occurs via consensus motifs. Targeted proteins are modified with 
multiple ubiquitin molecules rather than the attachment of a single moiety 
(Ciechanover et al., 1980). These multimers or ubiquitin chains are generated by 
isopeptide linkage between the C-terminus of preceding ubiquitin and the ε-amino 
group of following ubiquitin. Polyubiquitinated proteins modified in this fashion are 
detected as high molecular weight smears by Western blot analysis.  
 Ubiquitin is a 76 amino acid protein that contains seven lysine residues. 
Polyubiquitination usually occurs via Lys48 or Lys63 (Emmerich et al., 2011; Li and 
Ye, 2008). Lys48 linkages form more packed polymer structure, whereas Lys63-linked 
polyubiquitin exhibits an extended configuration (Tenno et al., 2004; Varadan et al., 
2004).  Lys48-linked ubiquitin chains signal degradation by targeting the proteins to 
26S proteasome. Lys48-linked tetra-ubiquitin is the minimal signal for proteasomal 
targeting and subsequent degradation. In contrast, Lys63-linked polyubiquitination is 
unable to target the proteins to proteasome, but rather serves as a regulatory 
posttranslational modification to modulate signaling pathways, ribosomal biogenesis, 
intracellular trafficking and DNA damage repair (Hochstrasser, 2004; Pickart and 
Fushman, 2004).  Unlike polyubiquitination, monoubiquitination is principally 
involved in the regulation of key cellular functions such as transcriptional activation 
(Hicke, 2001) and endocytosis (Haglund et al., 2003).  
 SUMO family proteins represent the most functionally diverse group of UBLs 
(Hay, 2005).  SUMO proteins have only ~18% sequence identity with ubiquitin but 
share high degree of three dimensional structure similarity to ubiquitin (Bayer et al., 
1998). SUMO, a ~11kDa protein, is highly conserved from yeast to mammals and 
preferentially conjugated mainly to consensus ψKXE/D motif (ψ represents a bulky 
hydrophobic residue, X any amino acid, and E/D acidic residues) on target proteins 
(Gareau and Lima, 2010). Yeast and invertebrates contain a single SUMO gene, 
whereas vertebrates have three SUMO paralogs: SUMO1, SUMO2 and SUMO3 
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(Matunis et al., 1996). SUMO1 has only ~50% identity with SUMO2 and SUMO3, 
and this difference is reflected by the functional diversity of these paralogs. Cells 
contain large amounts of unconjugated SUMO2 and SUMO3, whereas SUMO1 is 
mainly present as covalently attached to the major target RanGAP1 (Saitoh and 
Hinchey, 2000). Although there is little substrate preference for SUMO prologues in 
vitro, there is a considerable level of the substrate selectivity in vivo as RanGAP1 is 
preferentially conjugated with SUMO1, but not with SUMO2 or SUMO3.  Several 
other substrates display similar affinities towards different SUMO prologues. SUMO2 
and SUMO3 contain an N-terminal ψKXE/D motif that facilitates generation of 
polymeric SUMO conjugates or poly-SUMO chains, whereas SUMO1 is conjugated as 
a monomer (Tatham et al., 2001). 
I-1.2. Enzymatic cascades of protein modifications with ubiquitin and 
SUMO 
 Protein ubiquitination was first identified as an ATP hydrolysis-related 
enzymatic process of protein degradation (Ciechanover et al., 1980). Like many of 
eukaryotic regulatory systems, ubiquitination is regulated through enzymatic cascades. 
Although ubiquitin shares a homology with other UBLs, the conjugation cascade is 
mediated by distinct proteins/enzymes. Nascent UBL peptides are inactive and require 
an activating step before conjugation. UBLs are conjugated to target proteins via their 
C-terminus diglycine motif. Specific proteases called UBL-specific proteases cleave 
the C-terminal residues to expose the diglycine motif. The cleaved protein is then 
processed in the ubiquitin conjugation enzymatic cycle. Cleaved UBL proteins are first 
catalyzed by the activating enzyme E1. E1 is a heterodimeric protein complex 
containing an ATP hydrolysis subunit.  In enzymatic cycle for ubiquitination, energy 
derived from ATP hydrolysis is used to form the high energy thioester bond between 
ubiquitin and the E1 activating enzyme. The thioester-bound ubiquitin is then passed 
to an intermediary conjugation enzyme E2. Although there is no direct role of 
conjugation enzyme in the subsequent ligation, these intermediary enzymes reduce the 
activation energy requirements providing a rapid reaction.  In the final step, ubiquitin 
is conjugated to the target substrate by the action of an E3 protein ligase, which links 
the carboxy terminus of ubiquitin and the ε-amino group of the target lysine residue by 
bringing the substrate and E2-conjugated ubiquitin. Compared to the few numbers of 
E1 and E2 enzymes, the number of mammalian E3 enzymes has been greatly expanded. 
Mammalian genome encodes ~600 E3 ubiquitin ligases, which contribute to the 
substrate specificity of ubiquitination of their target proteins (Randow and Lehner, 
2009).  
 SUMO is conjugated to target proteins through an enzymatic cascade 
analogous to ubiquitin conjugation (Fig. I.1). First, C-terminal region of immature 
SUMO is cleaved, and the diglycine motif is exposed through the catalytic action of 
SUMO/sentrin-specific protease (SENP). Exposed C-terminal carboxyl group of 
cleaved SUMO is then adenylated by a heterodimeric enzyme Aos1/Uba2 (also called 
SAE1/SAE2) and conjugated through utilization of ATP. Activated SUMO is 
transferred through a thiol linkage to the Cys residue C173 in Uba2, which is 
transferred to another Cys residue of E2 conjugation enzyme, Ubc9, forming a 
thioester-SUMO conjugate (Johnson et al., 1997). Ubc9 is the only E2 conjugation 
enzyme that has been identified to date (Johnson and Blobel, 1997). Besides the 
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intermediary role in supplying activated SUMO, Ubc9 can directly mediate 
SUMOylation of target proteins through interaction with the consensus SUMOylation 
motif on target proteins in contrast to the ubiquitin conjugation where E3 catalytic 
activity is essential for target conjugation (Bernier-Villamor et al., 2002). SUMO E3 
ligases are proteins that catalyze transfer of SUMO to a target lysine residue.  SUMO 
E3 ligases catalyze the attachment of SUMO to target proteins by stabilizing the 
interaction between the target protein and the E2-SUMO conjugate.  
I-1.3. Ubiquitin E3 ligases 
 Eukaryotes have two distinct classes of ubiquitin E3 ligases with the specific 
features termed HECT (homologous to E6AP C-terminus) and RING (Really 
Interesting New Gene) domains. HECT is a ~350 amino acid domain localized at the 
C-terminus of the proteins. Human genome encodes for 28 HECT domain E3 ligases 
(Rotin and Kumar, 2009). HECT proteins are involved in broad biological pathways 
related to protein trafficking, cellular proliferation, tumorigenesis and immune 
response (Bernassola et al., 2008).  E6AP, also known as UBE3A, is a classic HECT 
domain-containing E3 ligase and interacts with various viral oncoproteins to facilitate 
degradation of tumor suppressor proteins such as p53 (Talis et al., 1998) or pRb 
(Munakata et al., 2007). Deletion of the UBE3A gene, which is paternally imprinted 
on human chromosome 15, leads to Angelman syndrome, a neurodevelopmental 
syndrome characterized by seizures, dementia and abnormalities in speech, sleep 
patterns and movement (Kishino et al., 1997). 
 The RING domain was first characterized as a Zn+2 binding stretch of amino 
acid sequence (Freemont et al., 1991). The RING domain is characterized by Cys and 
His residues occurring within a certain spacing dictated by the canonical motif: 
 Cys-X2-Cys-X(9-39)-Cys-X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-Cys-X2-Cys  
In this motif, Cys and His residues form the core of the structure to support the 
coordination of two Zn+2 atoms within the domain structure (Deshaies and Joazeiro, 
2009). The RING domain varies from the canonical zinc finger 
(X2-Cys-X2,4-Cys-X12-His-X3,4,5-His) in which cation coordination residues in 
RING are interspersed within random residues (Borden and Freemont, 1996). RING 
domain proteins interact with E2 conjugation enzymes that assist terminal E3 ligase 
reaction (Brzovic et al., 2006; Zheng et al., 2000). The RING domain surface is 
versatile and well conserved so that RING domain proteins interact with several 
cognate E2 conjugation enzymes via similar contact residues.  Point mutations of the 
zinc coordination residues in the RING domain induce a strong inhibition of the E3 
ligase activity (Deshaies and Joazeiro, 2009).  Therefore, these point mutations are 
widely used as negative controls for ubiquitination assays.  
I-1.4. SUMO E3 ligases 
 Unlike ubiquitination, SUMOylation is regulated by only several E3 SUMO 
ligases. To date, four SUMO E3 ligases have been well characterized. These SUMO 
E3 ligases are classified into two groups: RING domain-containing E3 ligases such as 
PIAS (Protein Inhibitor of Activated STAT) family and Nsmce2 (Nse2, Mms21), and 
non-RING E3 ligases such as RanBP2 and Cbx4 (chromobox homolog 4, Pc2).  
 The PIAS family proteins bind to Ubc9 and specific target proteins. Molecular 
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natures and functions of these family proteins are most extensively characterized 
among SUMO E3 ligases as described in the next section.  
 Nsmce2, a mammalian ortholog of yeast Mms21, is a component of Smc5/6 
complex (Structural Maintenance of Chromosome5/6) that is involved in homologous 
recombination, genomic stability and DNA repair (Potts, 2009).  Nsmce2 was 
identified as a SUMO E3 ligase in methyl methanesulfonate (MMS)-sensitive budding 
yeast mutants (Zhao and Blobel, 2005). Noteworthily, Nsmce1, another non-Smc5/6 
component, is a RING-type E3 ubiquitin ligase. Nsmce2 promotes SUMOylation of 
the Smc5/6 complex components Smc5, Smc6, Nsmce3 and Nsmce4 (Potts and Yu, 
2005). Nsmce2 stimulates SUMOylation of itself other than substrate proteins 
(Andrews et al., 2005). In contrast to other SUMO E3 ligases that promote conjugation 
with monomeric or dimeric SUMO, Nsmce2 substrates undergo conjugation with 
polymeric SUMO chains resulting in high molecular weight smears (Andrews et al., 
2005).  
 RanBP2 (also known as Nup358) is a 358-kDa component of nuclear pore 
complexes. RanBP2 is essential for nuclear protein import (Hutten et al., 2008).  
RanBP2 forms a stable complex with SUMO-conjugated RanGAP1 to stabilize it. A 
30-kDa domain of RanBP2 has SUMO-binding and catalytic activities but does not 
contain a RING domain. 
 Cbx4 is a member of Polycomb group (PcG) proteins, which form large 
multimeric complexes involved in transcriptional repression through forming protein 
complexes that promote histone methyltransferase activity. Cbx4 contains SUMO E3 
ligase activity for the transcriptional corepressor CtBP (Kagey et al., 2003). Cbx4 
recruits the CtBP to PcG bodies, and overexpression of Cbx4 leads to the enhancement 
of CtBP SUMOylation. Cbx4has been suggested to be involved in chromatin 
remodeling by promoting SUMOylation of several known SUMO targets such as 
histone deacetylases and topoisomerases.  
I-1.5. PIAS family SUMO E3 ligases 
 The largest group of SUMO E3 ligases is the PIAS family consisting of PIAS1, 
PIAS2, PIAS3, PIAS4, and their variants (Rytinki et al., 2009). They are identified as 
the negative regulators of STAT transcriptional activity, and thus named Protein 
Inhibitor of Activated Stat (PIAS). PIAS E3 ligases have distinct conserved domains. 
The SAP (SAF-A/Acinus/PIAS) domain at the N-terminus is responsible for 
subnuclear localization of the protein through binding to AT-rich DNA sequences 
present in nuclear matrix-attachment regions (Zhou et al., 2008). The PINIT 
(Pro-Ile-Asn-Ile-Thr) domain is a PIAS signature domain for PIAS1-4 (Rytinki et al., 
2009) and required for nuclear retention of PIAS3 (Duval et al., 2003). The catalytic 
domain of PIAS proteins contains the SP-RING (Siz/PIAS-RING) motif, a variant 
RING motif lacking two conserved Cys residues in the conventional RING motif 
(Hochstrasser, 2001).  The C-terminal domain of PIAS proteins is the least conserved 
domain that contains an acidic domain encompassing a SUMO-interacting motif (SIM). 
Moreover, the C-terminal domain has a Ser/Thr rich region common to all PIAS 
proteins except PIAS4 (Shuai, 2006). PIAS proteins have been shown to catalyze 
SUMOylation of ~60 different substrates (Shuai, 2006). Substrates of PIAS proteins 
are mainly transcription factors and their modifiers such as STAT (Liu et al., 1998), 
p53 (Kahyo et al., 2001), c-jun (Schmidt and Muller, 2002), Smad2/4 (Yang et al., 
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2013), PML (Rabellino et al., 2012) and CEBPβ (Liu et al., 2013). Posttranslational 
modifications of PIAS affect E3 ligase activities.  Phosphorylation of PIAS1 at the 
C-terminus by MAPK-activated protein kinase 2 stimulates E3 ligase activity towards 
p53 (Heo et al., 2013). Furthermore, SUMOylation of PIAS4 promotes E3 ligase 
activity towards TCF4 in vivo (Ihara et al., 2005).  However, detailed molecular 
mechanisms underlying regulation of PIAS SUMO E3 ligases remain elusive. 
I-2. Specific Introduction  
I-2.1. Necdin and MAGE family 
Necdin was originally identified in 1991 as a hypothetical protein encoded by an 
mRNA expressed in neurally differentiated P19 embryonal carcinoma cells 
(Maruyama et al., 1991). In the same year, a tumor antigen, originally named MZ2-E, 
which induced a cytotoxic response by autologous T-cells, was discovered (van der 
Bruggen et al., 1991). MZ2-E was later identified as one of the human 12 hMAGEA 
genes cluster on X-chromosome (De Plaen et al., 1994) and named MAGEA1 
(Chomez et al., 2001).  Homologous sequences are consequently identified on 
different clusters and named MAGEB (Muscatelli et al., 1995) and MAGEC (Lucas et 
al., 1998) gene families. MAGEA, MAGEB and MAGEC proteins are encoded in a 
single terminal exon. Interestingly expression of MAGEA, MAGEB and MAGEC 
genes are highly restricted to cells of tumor origin, germ cells, testis and placenta 
(Barker and Salehi, 2002).  These proteins were also called CTA (Cancer-Testis 
Antigens) (Fratta et al., 2011; Old and Chen, 1998). The restricted expression is due to 
extensive methylation of the promoter regions of MAGEA, MAGEB and MAGEC 
gene clusters in normal tissues (De Smet et al., 1995). Although expression of 
MAGEA, MAGEB and MAGEC proteins has been identified in cancers of different 
origin, physiological or pathophysiological functions of these MAGE family proteins 
remain largely unknown.  
Necdin and MAGE proteins share a large homologous region known as the MAGE 
homology domain (MHD). Mammalian MAGE family proteins are divided into two 
classes based on the sequence similarities of the MHDs and gene expression patterns 
(Barker and Salehi, 2002; Chomez et al., 2001) (Fig. I.2A).   Type I MAGEs such as 
MAGEA, MAGEB, and MAGEC subfamilies are expressed in cancer and male germ 
cells but not in normal cells, and their genes are located on chromosome X (van der 
Bruggen et al., 1991). In contrast, Type II MAGEs such as necdin, necdin-like 2 
(NDNL2, also known as MAGEG1), MAGED, MAGEE, MAGEF, MAGEH, and 
MAGEL are expressed in normal cells including neural cells.  Type II MAGE 
proteins are further divided into two groups based on the MHD domain similarities. 
First subgroup consists of proteins of low molecular weight (<350 residues) with high 
MHD similarities to necdin including necdin-like 2, MAGEF1 and MAGEH1. The 
other subgroup includes proteins of higher molecular weight and an extended 
N-terminal region that share high MAGED1 MHD similarity. This subgroup consists 
of MAGED1-D4, MAGEE1 and MAGEL2 (originally named necdin-like 1).  These 
two distinct subgroups are suggested to exert distinct functional and biochemical 
effects. However, biochemical roles of Type II MAGE proteins based on the 
differences in the overall structure and MHD sequence remain to be elucidated. 
I.	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 Among Type II MAGE proteins, necdin, MAGEL2 and necdin-like 2 (Chibuk et 
al., 2001) are encoded by the genes that are closely located on human chromosome 15.  
Human necdin (NDN) and MAGEL2 genes are located at chromosome 15q11-12, a 
region responsible for the pathogenesis of the classic genomic imprinting-associated 
neurodevelopmental disorder Prader-Willi syndrome (Jay et al., 1997; Kozlov et al., 
2007; Lee et al., 2000; MacDonald and Wevrick, 1997; Nakada et al., 1998).  Both 
necdin and MAGEL2 are expressed only from the paternal alleles and implicated in 
the neural development based on the phenotypes of gene knockout mice (Gerard et al., 
1999; Kuwako et al., 2005; Lee et al., 2000; Muscatelli et al., 2000).  In contrast to 
necdin and its homologous MAGE proteins, there is limited information about 
biochemical functions of most MAGE family proteins. 
 
I-2.2. Expression and function of necdin 
 Necdin was first isolated from a subtraction cDNA library of murine P19 
embryonal carcinoma cells neurally differentiated by retinoic acid treatment 
(Maruyama et al., 1991). The necdin gene (Ndn) encodes a 325-amino acid protein, 
which contains a highly conserved core domain (aa 83-292) with 91% identity 
between mouse and human and a less conserved highly-disordered N-terminus 
(Uetsuki et al., 1996; Nakada et al., 1998). Necdin is abundantly expressed in 
postmitotic neurons distributed in the central and peripheral nervous systems of mice 
(Aizawa et al., 1992). Although it was initially thought that necdin expression was 
restricted to postmitotic neurons and skeletal muscle cells (Uetsuki et al., 1996), 
necdin is also expressed in neuroepithelial stem cells or neural stem cells (Huang et al., 
2013; Minamide et al., 2014). The human necdin gene (NDN) is located on the 
chromosomal region 15q11, which is implicated in the pathogenesis of the 
neurodevelopmental Prader-Willi syndrome (PWS). In this region, maternal NDN and 
several other genes are silenced through genomic imprinting (Jay et al., 1997; 
MacDonald and Wevrick, 1997; Nakada et al., 1998). 
 Studies on molecular function of necdin have been initiated by screening of 
cDNA libraries by yeast two-hybrid assay to elucidate biochemical interaction partners 
of necdin. Necdin interacts with viral transforming proteins Simian virus 40 (SV40) 
large T antigen and adenovirus E1A, also with cellular transcription factor E2F1 
(Taniura et al., 1998). These proteins are known as binding partners of the 
retinoblastoma (Rb) protein, and necdin interacts with the Rb-binding domain of these 
proteins, suggesting a functional similarity between necdin and Rb. Furthermore, 
necdin induces growth suppression on SAOS2 cells deficient in Rb, and necdin 
suppresses apoptosis by E2F1 in N1E-115 neuroblastoma cells (Kobayashi et al., 
2002)(Kobayashi 2002). Necdin also interacts with p53, another growth suppressor, to 
suppress p53-induced transactivation and apoptosis without affecting the growth 
suppressive function of p53 (Taniura et al., 1999).  These data taken together suggest 
that necdin is a tumor suppressor-like protein that interacts with viral oncogenes and 
their cellular targets.  
 Necdin interacts with p75 neurotrophin receptor, a transmembrane protein to 
facilitate differentiation (Tcherpakov et al., 2002).  It interacts with Msx2 
homeodomain protein via MAGED1 and modulates Msx2-dependent transcriptional 
activities (Kuwajima et al., 2004). Moreover, necdin inhibits apoptosis by suppressing 
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E2F1-dependent transcription of cyclin-dependent protein kinase cell division cycle 2 
(Cdc2, also known as Cdk1) (Kurita et al., 2006) and by facilitating Sirt1-mediated 
deacetylation of p53 (Hasegawa and Yoshikawa, 2008). Necdin-induced growth 
suppression occurs not only in transformed cell lines but also in primary preadipocytes 
(Fujiwara et al., 2012) and neural precursor cells, in which necdin interacts with HIF2α 
(Huang et al., 2013) and Bmi1 (Minamide et al., 2014).  Furthermore, Drosophila 
MAGE protein (the sole MAGE protein in Drosophila), like necdin, regulates neural 
precursor cell proliferation (Nishimura et al., 2008).  In hematopoietic stem cells, 
necdin also exerts growth suppressive effect (Kubota et al., 2009). These findings 
suggest that necdin regulates proliferation of neuronal and non-neuronal 
stem/progenitor cells by interacting with many proteins involved in the cell cycle and 
cellular differentiation. 
I-2.3. MAGE proteins and posttranslational modifications with ubiquitin 
 It has been reported that several Type I MAGE proteins interact with RING 
ubiquitin E3 ligases and that the interaction promotes their E3 ligase catalytic activities 
(Doyle et al., 2010). MAGE family proteins interact differentially with E3 RING 
ubiquitin ligases.  For example, MAGEA2, MAGEA3, MAGEA6, MAGEC2, and 
MAGED1 directly bind to TRIM28 E3 RING ubiquitin ligase, whereas MAGEF1 and 
NDNL2 (MAGEG1) interact with NSE1 (Fig. I.2B). The crystal structure of 
NDNL2-NSE1 provides structural insights into MAGE family proteins and their 
interaction with E3 RING ubiquitin ligases (Doyle et al., 2010). In addition, these 
RING E3 ubiquitin ligase-interacting MAGE proteins enhance the ubiquitin ligase 
activity.  For example, a MAGEC2-TRIM28 complex ubiquitinates and targets p53 
for proteasomal degradation. Thus, MAGE proteins may serve as modulators of RING 
domain-containing ubiquitin E3 ligases. In contrast, effects of the MAGE proteins on 
the regulation of RING type E3 SUMO ligases remain elusive.  Because similar roles 
of MAGE proteins in the regulation of SUMO E3 ligases are suggested, we investigate 
the roles of MAGE proteins in the regulation of SUMO E3 ligases. 
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I-3. Figures I.1, 2 
 
 
Figure I.1  Schematic description of SUMO conjugation enzymatic cascade. 
Figure I.2.  MAGE family proteins modulate RING ubiquitin E3 ligases 
differentially.  
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Figure I.1  Schematic description of SUMO conjugation enzymatic cascade. 
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Ubiquitin E3 ligase Human MAGE protein 
TRIM28 A2, A3, A6, C2, D1 
LNX1 B18 
NSE1 F1, G1 (NDNL2) 
TRIM27 D4B, F1, L2 
Praja-1 D1, G1 
A 
B 
Figure I.2.  MAGE family proteins modulate RING ubiquitin E3 ligases 
differentially.  
(A) Phylogenetic tree presentation of MAGE family proteins.  (B) Summary of 
interactions between ubiquitin E3 ligases and human MAGE proteins.  Data are 
taken from Doyle, J. et al. (2010) 
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II. EXPERIMENTAL PROCEDURES 
II-1. cDNAs and plasmids 
Full-length cDNAs encoding mouse Nsmce1 (NCBI NM_026330.3), Nsmce2 
(NCBI NM_026746.3), Cbx4/Pc2 (NCBI NM_007625.2) and PIAS1 (NCBI 
NM_019663.3) were cloned from mouse E14.5 forebrain cDNA library and subcloned 
into 6xMyc(N)-pcDNA3.1(+) vector (Hasegawa et al., 2012).  Expression vectors for 
mouse p53, necdin, and their deletion mutants were constructed as described (Huang et 
al., 2013; Taniura et al., 2005).  cDNAs for mouse MAGED1, necdin-like2 and 
MAGEL2 were cloned as described (Kuwajima et al., 2004; Kuwako et al., 2004).  
Human MAGEF1 was cloned from nuclear DNA library of HEK293A cells.  Human 
MAGEA1 cDNA was provided by Dr. Kyogo Itoh (Kurume University School of 
Medicine).  cDNAs encoding PIAS1 aa 1-100, 101-300, 301-400 and 401-652 or 
deletion mutants aa 101-652 and 1-400 were generated using synthetic oligonucleotide 
primers and subcloned into the expression vector. cDNAs encoding full-length mouse 
STAT1 (NCBI NM_001205313.1) and PML (NCBI NM_008884.5) were cloned from 
cDNA libraries of E14.5 mouse forebrain and adult mouse spleen, respectively, and 
subcloned into p3xFLAG-CMV10 (Sigma-Aldrich).  cDNA encoding mouse SUMO1 
was obtained from RIKEN BioResource Center DNA Bank and subcloned into 
hemagglutinin (HA)-pcDNA3.1(+) carrying the N-terminal HA sequence.  All cDNAs 
used were sequenced for their identities.  Experiments were approved by Recombinant 
DNA Committee of Osaka University (Approval No. 2938-1) and performed in 
accordance with national and institutional guidelines. 
 
II-2. Co-immunoprecipitation assay  
HEK293A cells (1 x 106 cells per 60 mm dish) were transfected with 
combinations of expression vectors, incubated in Dulbecco's Modified Eagle Medium 
(Life Technologies) supplemented with 10% fetal bovine serum at 5% CO2 at 37°C, and 
harvested 24 hrs after transfection as described (Taniura et al., 1998).  The total 
amount of infected DNA was equalized by adding pcDNA3.1(+) vector. Transfected 
cells were lysed in a lysis buffer containing 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 
mM EDTA, 1% IGEPAL CA-630 (Sigma-Aldrich), 10% glycerol, and protease 
inhibitors (Complete, Roche). Lysates (200 µg) were incubated at 4°C for 2 hrs with 
antibodies to FLAG (M2; Sigma-Aldrich; 1:100), Myc (9E10; 1:10) and necdin 
(NC243; 1:200)(Niinobe et al., 2000).  Proteins bound to antibodies were pelleted with 
protein A-Sepharose (GE Healthcare), eluted from protein A-Sepharose, separated by 
10% SDS-PAGE, and electroblotted onto polyvinylidene difluoride membranes 
(Immobilon; Millipore).  Membranes were incubated with antibodies to Myc (1:10), 
FLAG (1:500), necdin (1:3000), HA (HA.11; Covance; 1:100), β-tubulin (TUB 2.1; 
Sigma-Aldrich; 1:1000) and γ-tubulin (GTU-88;Sigma-Aldrich; 1:1000) at room 
temperature for 1 hr.  After incubation with horseradish peroxidase-conjugated 
anti-mouse and anti-rabbit IgGs (Cappel) for 1 hr at room temperature, proteins were 
visualized with chemiluminescence reagents (Western Lightning Plus-ECL, 
PerkinElmer).  
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II-3. SUMOylation assay  
 HEK293A cells (1 x 106 cells per 60 mm dish) were transfected with combinations 
of expression vectors for HA-SUMO1, Myc-PIAS1, necdin, FLAG-STAT1 and 
FLAG-PML and harvested 24 hrs after transfection. For analysis of PML SUMOylation, 
cells were treated with 10 µM MG132 (Peptide Institute) 4 hrs prior to harvest as 
described (Rabellino et al., 2012). Cells were lysed in the lysis buffer supplemented 
with 20 mM N-ethylmaleimide, and the lysates (300 µg) were incubated at 4°C for 2 hrs 
with anti-FLAG antibody (M2; Sigma-Aldrich).  The protein-antibody complexes 
were pelleted with protein A-Sepharose, separated by 10% SDS-PAGE, and detected by 
Western blotting as above. Signal intensities of sumoylated proteins were quantitated by 
densitometry with ImageJ1.48 software. The protein concentration was determined by 
the Bradford method (Bio-Rad).   
 
II-4. Reporter assay  
 Luciferase reporter assay for p53-driven transactivation was performed using a 
2.4-kilobase pair fragment of human p21/WAF1 promoter inserted into the luciferase 
reporter vector PGV-G (Toyo Ink) as described previously (Taniura et al., 1999).  
Combinations of expression vectors for Flag-p53, HA-PIAS1, necdin, and 
GFP-SUMO1 were transfected along with promoter-reporter into HEK293A cells.  
Transfectants were harvested 36 hr after transfection, and luciferase activities were 
measured with a luminometer (Lumat LB9501, Berthold) using Dual-Luciferase 
Reporter Assay system (Promega). Transfection efficiency was normalized with the 
activity of co-expressed Renilla luciferase.  
 
II-5. Ubiquitination assay  
 HEK293A cells (1 x 106 cells per 60 mm dish) were transfected with combinations 
of expression vectors for FLAG-tagged ubiquitin, HA-tagged ubiquitin, Myc-tagged 
full-length PIAS1, Myc-tagged PIAS1 deletion mutants, necdin, FLAG-tagged necdin, 
FLAG-tagged MAGEA1, and FLAG-tagged necdin-like 2.  Transfected cells were 
incubated for 20 hrs, treated with 30 µM MG132 or DMSO (vehicle control) for 4 hrs, 
and harvested.  Cells lysates (250 µg) were incubated at 4°C for 2 hrs with the 
anti-Myc antibody, and the protein-antibody complexes were pelleted with protein 
A-Sepharose, separated by 10% SDS-PAGE, and detected by Western blotting as above.  
Signal intensities of ubiquitinated proteins were quantitated by densitometry.  
 
II-6. Immunocytochemistry 
HEK293A cells (2-4 x 105 cells per 35 mm dish) were cultured on coverslips for 
17 hrs, transfected with expression vectors, and incubated for another 24 hrs at 5% CO2 
at 37°C.  Cells were fixed with 10% formalin for 20 min at room temperature and 
permeabilized with methanol for 20 min at room temperature.  For proteasome 
inhibition, transfected cells were incubated in the presence of 30 µM MG132 or DMSO 
for 4 hrs prior to fixation.  For immunostaining of the nuclear matrix-associated 
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proteins, cells were sequentially treated with 0.5% Triton X100, 25 U/ml RNase-free 
DNase (RQ1, Promega), 0.25 M ammonium sulfate and 2M NaCl according to the 
method described (He et al., 1990; Taniura and Yoshikawa, 2002).  Fixed cells were 
treated with PBS-Tween 20 containing 1% BSA (Sigma-Aldrich) for 1 hr at room 
temperature, incubated with primary antibodies to Myc (Cell Signaling; 1:300), necdin 
(NC243;1:1000) and NuMA (Ab-1, Oncogene;1:100) overnight at 4ºC, and with Alexa 
Fluor 488-conjugated anti-mouse (or anti-rabbit) IgG (Life Technologies;1:1000) and 
cyanine 3-conjugated anti-rabbit (or anti-mouse) IgG (Jackson ImmunoResearch, 1:500). 
Chromosomal DNA was stained with 3.3 µM Hoechst 33342 (Sigma-Aldrich). Stained 
cells were observed with a fluorescence microscope (BX-50-34-FLAD1, Olympus), and 
images were captured with a charge-coupled device camera system (DP-70; Olympus). 
 
II-7. Lentivirus infection 
Recombinant lentiviruses were produced in HEK293FT cells by transfecting SIN 
vector plasmids and two helper plasmids as described previously (Fujiwara et al., 2012; 
Miyoshi et al., 1998). Necdin cDNAs were subcloned into pENTR1A entry vector (Life 
Technologies) to construct CSII-EF1α-necdin-IRES-EmGFP, in which Emerald Green 
Fluorescent Protein (EmGFP) (Life Technologies) was used for an expression indicator 
(Minamide et al., 2014).  The viral titer was measured by serial dilution on HEK293FT 
cells (Life Technologies) and determined as GFP-positive cell population by 
immunocytochemistry. Lentivirus vectors for EmGFP (empty vector) or necdin 
(+EmGFP) were infected into H1299 cells at a multiplicity of infection (MOI) of 12, 
and the infected cells were incubated for 72 hrs prior to analyses.  Expressed proteins 
were analyzed by Western blotting using antibodies against PIAS1 (EPR2518Y, 
Abcam; 1:5000), necdin, and γ-tubulin. Signal intensities of proteins were quantitated 
by densitometry. 
 
II-8. Cell proliferation assay 
 H1299 cells were plated on coverslips in 12-well plates (1 x 105 cells per well), 
cultured for 24 hrs and infected with lentiviruses expressing EmGFP and necdin.   
BrdU (10 µM) was added 48 hrs after viral infection, incubated for another 4 hrs. Cells 
were fixed with 10% formalin for 20 min at room temperature and permeabilized with 
methanol for 20 min at room temperature. BrdU was detected by fluorescence 
immunocytochemistry as described in (Fujiwara et al., 2012; Taniura et al., 1999).  
The proliferation rate was expressed as BrdU-positive cells per total cells, which were 
counterstained with 5 µM Hoechst 33342. 
II-9. Statistics 
Statistical significance was tested using Tukey-Kramer multiple comparison 
method unless otherwise stated.  A significance of p<0.05 was required for rejection of 
the null hypothesis. 
III.	  RESULTS	  
	  
 19 
III. RESULTS 
 
III-1. MAGE proteins differentially interact with SUMO E3 ligases 
 We first analyzed the interactions of typical SUMO E3 ligases including Nsmce2, 
Cbx4 and PIAS1 with MAGE proteins including necdin, MAGEA1, MAGED1, 
MAGEF1, necdin-like 2 and MAGEL2 by co-immunoprecipitation assay.  To verify 
the assay system, we used the RING-type protein (non-SMC element 1) which 
interacts with necdin-like 2 and MAGEF1 but not with necdin, MAGED1 and 
MAGEL2 (Doyle et al., 2010).   We found that Nsmce1 interacted with MAGEA1, 
necdin-like 2 and MAGEF1, but not with necdin, MAGED1 or MAGEL2 (Fig. III. 
1A). We next examined the interactions of the SUMO E3 ligases Nsmce2, Cbx4, and 
PIAS1 with these MAGE proteins (Fig. III.1B-D).  The MAGE proteins except 
MAGEA1 failed to interact with Nsmce2 and Cbx4 (Fig. III.1B, C).  Intriguingly, 
PIAS1 interacted with necdin, MAGEA1, MAGED1, MAGEF1 and MAGEL2, but 
not with necdin-like 2 (Fig. III.1D). These data indicate that PIAS1 is a common 
target of diversified mammalian MAGE proteins.   
 
III-2. Necdin and PIAS1 interact each other through conserved 
domains 
 To characterize the interaction between necdin and PIAS1, we constructed 
deletion mutants of PIAS1 and necdin for co-immunoprecipitation assay using Human 
Embryonic Kidney 293A (HEK293A) cells (Fig. III. 2A).  The PIAS1 mutants were 
designed to contain PIAS-specific motifs: PIAS1 amino acids (aa) 1-100 (NT) 
containing the SAF-Acinus-PIAS (SAP) domain; PIAS1 aa 101-300 (PD) containing 
the Pro-Ile-Asn-Ile-Thr (PINIT) domain; PIAS1 aa 301-400 (SR) containing the 
Siz/PIAS RING (SP-RING) domain; PIAS1 aa 401-651 (CT) containing the SIM 
(SUMO-interactive motif) and Ser/Thr-rich domains.  We constructed necdin mutants 
such as necdin aa 1-100 (NT) containing N-terminal proline-rich acidic region, necdin 
aa 101-325 (CT) containing the entire MAGE homology domain (MHD) (aa 116-280) 
and necdin ΔH4/5 (aa 190-222 deletion) lacking the p53-interacting region (Taniura et 
al., 2005), which corresponds to helices H4 and H5 region of necdin-like 2 MHD 
(PDB 3NW0) (Doyle et al., 2010; Hudson et al., 2011).  Necdin was 
co-immunoprecipitated with the PIAS1 fragments containing the PINIT (PD) and 
SP-RING (SR) domains, and these were conversely co-immunoprecipitated with 
necdin (Fig. III.2B).  Necdin failed to interact with the PIAS1 terminal regions.  In 
this assay, we confirmed that necdin bound to p53 (positive control) but not to 
N-terminally truncated p53 (p53 ΔN, negative control)(Taniura et al., 1999). 
 We then analyzed the PIAS1-binding region of necdin using HEK293A cells 
transfected with truncated necdin mutants (Fig. III.3A).  PIAS1 interacted with 
full-length necdin and the N-terminally truncated mutant (CT) but not with the 
N-terminal region (NT).  We also found that full-length necdin and CT reduced 
expression levels of Myc-PIAS1, suggesting that co-expressed necdin destabilizes the 
PIAS1 protein (Fig. III.3B, third panel).  To confirm whether the necdin MHD is 
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required for PIAS1 binding, we used the p53 binding-defective mutant necdin∆H4/5 
(Fig. III.3C). This mutant failed to bind to PIAS1 or p53 (control), suggesting that the 
H4/5 region of the MHD is indispensable for the interaction between necdin and 
PIAS1.  
 Homology modeling based on the X-ray crystallographic data of necdin-like 2 
(Doyle et al., 2010) revealed that the mouse necdin aa 191-222 region corresponds to 
helices 4 and 5 in the winged-helix motif B (WH-B) (Fig. III.4A, B).  The H4/5 
region in necdin-like 2 is predicted to form a hydrophobic pocket that interacts with 
NSMCE4A (Hudson et al., 2011).   We have previously found that this deletion 
mutant neither induces cell growth suppression nor associates with the nuclear matrix 
(Taniura et al., 2005).  Because MAGE proteins such as MAGEA1, MAGED1, 
MAGEF1 and MAGEL2 interact with PIAS1 as shown Fig. III.1D, it is possible that 
the PIAS1-binding domains of these MAGE proteins take configurations similar to 
that of necdin.  In contrast, necdin-like 2, which shows structural and functional 
similarities to necdin (Kuwako et al., 2004), failed to interact with PIAS1.  
Necdin-like 2 bears five amino acid substitutions in the H4/5 region compared with 
PIAS1-interacting MAGE proteins (Fig. III.4C).  It is noteworthy that three Thr 
residues are present in and near the H5 region of necdin-like 2, whereas other MAGE 
proteins contain only one or no Thr residue in their H4/5 regions.  We speculate that 
necdin-like 2 lacks PIAS1 binding owing to its unique configuration of the H4/5 
region.  
III-3. Necdin inhibits PIAS1 SUMO E3 ligase activity 
 Since necdin interacted with the PINIT and SP-RING domains that constitute the 
catalytic region of PIAS1 (Liang et al., 2004), we investigated whether necdin affects 
the SUMO E3 ligase activity of PIAS1.  We examined the effects of necdin on 
PIAS1-dependent SUMOylation using HEK293A cells transfected with SUMO1 and 
the PIAS1 substrates STAT1 (Liu et al., 1998) and PML (Rabellino et al., 2012).  
Because the PIAS1 protein level was decreased by co-expressed necdin, we used twice 
the amount of the PIAS1-expressing vector to avoid reducing the PIAS1 enzyme level.  
In this assay, faint bands of sumoylated STAT1 were detected at ~95 kDa in the 
absence of PIAS1, and PIAS1 promoted STAT1 SUMOylation to 5.2 times the control 
level (Fig. III.5A, B). Co-expression of necdin suppressed the PIAS1-promoted 
STAT1 SUMOylation level by 57%. Similarly, PIAS1 markedly increased the level of 
sumoylated PML (6.6 times the control level) detected as smeared bands at >150 kDa, 
and co-transfection of necdin decreased the PML SUMOylation level by 54% (Fig. 
III.6A, B).  We also found that PIAS1-dependent SUMOylation of p53 was reduced 
by co-expression of necdin (Fig. III.7).  We then examined the effect of necdin on 
PIAS-mediated activation of p53-dependent transcription using the human p21/WAF1 
promoter containing the p53-binding motif and luciferase reporter system (Fig. III.8).  
Both PIAS1 and SUMO1 enhanced p53-mediated transcription activities, and necdin 
markedly reduced the enhancement.  These data taken together suggest that necdin 
suppresses the SUMO E3 ligase activity of PIAS1.  
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III-4. Necdin promotes proteasomal degradation of PIAS1 
 In the preceding experiments, PIAS1 protein levels were reduced when necdin 
was co-expressed.  Thus, we examined whether necdin affects the stability of PIAS1 
using transfected HEK293A cells (Fig. III.9A).  Necdin reduced the PIAS1 level in a 
dose-dependent manner.  To examine whether necdin degrades the PIAS1 protein via 
the ubiquitin-proteasomal pathway, we used the proteasome inhibitor MG132.  
Treatment with MG132 protected PIAS1 from necdin-promoted degradation (Fig. 
III.9B), suggesting that necdin promotes PIAS1 degradation in the proteasome.   
 We then examined whether necdin promotes PIAS1 ubiquitination by 
immunoprecipitation assay using HEK293A cells transfected with ubiquitin cDNA 
(Fig. III.9C),  Ubiquitinated PIAS1 was detected as multiple bands at 100-250 kDa.  
Although the ubiquitinated PIAS1 level was reduced, presumably owing to the 
degradation of the PIAS1 protein, in the absence of MG132, necdin significantly 
promoted PIAS1 ubiquitination in the presence of MG132 (Fig. III.9D). These data 
indicate that necdin promotes PIAS1 degradation in the ubiquitin-proteasome system.   
To analyze the specificity of necdin in PIAS1 degradation, we examined the effects of 
MAGEA1 and necdin-like 2 on PIAS1 ubiquitination in the presence of MG132.  
MAGEA1 promoted ubiquitination of PIAS1 to a significant but lesser extent than 
necdin, whereas necdin-like 2 exerted little or no ubiquitination-promoting effect (Fig. 
III.10A, B). We also found that the necdin ΔH4/5 mutant failed to promote PIAS1 
ubiquitination (Fig. III.10C, D). 
 We next examined the subcellular localization of PIAS1 and necdin by 
immunocytochemistry using transfected HEK293A cells.  PIAS1 was localized 
exclusively in the nucleus, whereas necdin was in both the nucleus and the cytoplasm 
(Fig. III.11A).  Although co-expression of necdin and PIAS1 did not alter their 
subcellular localization patterns, co-expressed necdin markedly reduced nuclear PIAS1 
signals.  We then examined the effects of MG132 on the distribution and expression 
levels of PIAS1 (Fig. III.11B).  MG132 per se had little or no effect on the 
localization of PIAS1 or necdin, but suppressed the necdin-induced reduction of 
nuclear PIAS1 levels.  We classified PIAS1(Myc)-expressing cells into three groups 
by relative fluorescence intensities; undetectable or barely detectable, low, and high 
(Fig. III.11C, D).  The PIAS1 immunoreactivity in 55% of necdin-positive cells was 
undetectable or barely detectable in the absence of MG132, whereas 52% of 
necdin-immunopositive cells had high fluorescence intensities in the presence of 
MG132, suggesting that necdin promotes degradation of nuclear PIAS1 in the 
proteasome. 
III-5. PIAS1 N- and C-terminal regions are required for 
necdin-dependent ubiquitination  
 To determine the PIAS1 regions responsible for necdin-dependent degradation, 
we transfected HEK293A cells with PIAS1 mutants lacking the N-terminus (∆NT) and 
C-terminus (∆CT)(Fig. III.12A).  As expected, these truncated mutants, which 
contain the central conserved domains, bound to necdin (Fig. III.12B).  Although 
necdin significantly reduced the full-length PIAS1 level, PIAS1∆NT and ∆CT mutants 
were resistant to necdin-promoted degradation (Fig. III.13A, B).   We also examined 
whether these mutants undergo necdin-dependent ubiquitination (Fig. III.13C).  
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PIAS1ΔNT was resistant to necdin-promoted ubiquitination, whereas PIAS1∆CT 
underwent robust ubiquitination in a necdin-independent manner.  These results 
suggest that these PIAS1 terminal regions mediate the susceptibility of PIAS1 to 
necdin-dependent ubiquitination. 
 
III-6. Necdin alters subcellular localization of PIAS1 
 To investigate the mechanism whereby the terminal truncation of PIAS1 affects 
necdin-dependent ubiquitination, we analyzed the subcellular localization of 
ectopically expressed PIAS1 mutants in HEK293A cells.  The full-length PIAS1 and 
PIAS1ΔNT were distributed in the nucleus, whereas PIAS1ΔCT localized 
predominantly in the cytoplasm (Fig. III.14A).  All of the full-length and mutant 
PIAS1 (Myc)-transfected cells showed similar distribution patterns.  PIAS1ΔNT 
partially accumulated as nuclear speckles that were immunopositive for PML (Fig. III. 
14B), consistent with the previous observation that a PIAS1 mutant lacking the SAP 
domain localizes to the PML bodies (Sudharsan and Azuma, 2012).  Because PIAS4 
localizes in the nuclear matrix via its N-terminal SAP domain (Sachdev et al., 2001), 
we immunocytochemically examined the localization of these mutants in the nuclear 
matrix (Fig. III.15).  Necdin localized in the nuclear matrix and accumulated as 
distinct speckles, consistent with the previous findings (Taniura and Yoshikawa, 2002).  
Full-length PIAS1 localized in the nuclear matrix of all of the transfected 
immunopositive cells, whereas PIAS1 deletion mutants were totally undetectable in 
the nuclear matrix, suggesting that the N- and C-terminal regions of PIAS1 are 
indispensable for its nuclear matrix localization. 
 
III-7. Necdin suppressed endogenous expression of PIAS1  
 To assess the physiological role of the interaction between necdin and PIAS1, we 
determined whether necdin induces degradation of the PIAS1 protein in an assay 
system where stable expression system is employed.   
 To examine whether ectopic expression of necdin promotes degradation of 
endogenous PIAS1, we infected H1299 cells, a human non-small cell lung carcinoma 
cell line that endogenously expresses PIAS1 at a relatively high level (Rabellino et al., 
2012), with necdin-expressing lentivirus vector and analyzed the PIAS1 levels (Fig. 
III.16). Under the conditions where most of H1299 cells were infected with the control 
EmGFP vector (Fig. III.16A), necdin overexpression significantly reduced the 
endogenous PIAS1 levels (Fig. III.16B, C).  We also examined the effect of necdin 
on the proliferation of stably necdin-expressing H1299 cells by BrdU incorporation 
assay. We observed that necdin overexpression significantly reduced the number of 
BrdU-positive dividing cells (Fig. III.16D, E).  
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III-8. Figures III.1-16  
 
 
 
Figure III.1  MAGE proteins differentially interact with Nsmce1, Nsmce2, Cbx4 and 
PIAS1. 
 
Figure III.2  Necdin interacts with PIAS1 central conserved domains. 
 
Figure III.3  Necdin interacts with PIAS1 via conserved amino acid stretch on MHD. 
 
Figure III.4  Necdin interacts with PIAS1 via a hydrophobic pocket region of MHD. 
 
Figure III.5  Necdin inhibits PIAS1-dependent sumoylation of STAT1. 
 
Figure III.6  Necdin inhibits PIAS1-dependent sumoylation of PML. 
 
Figure III.7  Necdin inhibits PIAS1-dependent sumoylation of p53. 
 
Figure III.8  Necdin cancels PIAS1-dependent stimulation of p53 transcriptional 
activity. 
 
Figure III.9  Necdin promotes PIAS1 degradation via the ubiquitin-proteasome 
pathway. 
 
Figure III.10  Necdin specifically promotes PIAS1 ubiquitination. 
 
Figure III.11  Necdin reduces nuclear PIAS1 levels in transfected cells. 
 
Figure III.12  PIAS1 terminal-truncated mutants interact with necdin. 
 
Figure III.13  PIAS1 terminal-truncated mutants lack necdin-dependent ubiquitination.  
 
Figure III.14  Subcellular localization of PIAS1-truncated mutants. 
 
Figure III.15  PIAS1 terminal-truncated mutants dissociate from the nuclear matrix.  
 
Figure III.16  Lentivirus- mediated expression of necdin reduces endogenous PIAS1 
levels.  
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Figure III.1 MAGE proteins differentially interact with Nsmce1, Nsmce2, Cbx4 and PIAS1.  
(A-D) Interactions of MAGE proteins with Nsmce1, Nsmce2, Cbx4, and PIAS1.  
Expression vectors for FLAG-tagged necdin (ND, 2 µg), MAGEA1 (A1, 1 µg), 
MAGED1 (D1, 8 µg), MAGEF1 (F1, 4 µg), necdin-like 2 (NL, 1 µg), and MAGEL2 
(L2, 6 µg) were co-transfected with expression vectors for Myc-tagged Nsmce1 
(Myc-Nsmce1, 3 µg)(A), Nsmce2 (Myc-Nsmce2, 3 µg)(B), Cbx4 (Myc-Cbx4, 3 µg)(C), 
and PIAS1 (Myc-PIAS1, 6 µg)(D) into HEK293A cells.  Proteins were 
immunoprecipitated (IP) with anti-FLAG antibody (FLAG) and immunoblotted (IB) with 
anti-Myc (Myc) (top panels, A-D).  Expressed proteins were immunoblotted (IB) with 
antibodies to Myc, FLAG and β-tubulin (Tub). Molecular sizes are in kilodaltons (kDa). 
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Figure III.2  Necdin interacts with PIAS1 central conserved domains. 
(A) Domain structure of mouse PIAS1 Abbreviations: FL, full-length; NT, N-terminus; CT, 
C-terminus; SAP, SAF-Acinus-PIAS; PD, PINIT motif-containing domain; SR, SP-RING; 
SIM, SUMO-interacting motif; S/T, Ser/Thr-rich.   
(B) Interactions of necdin with PIAS1 deletion mutants. HEK293A cells were transfected 
with combinations of expression vectors for necdin (3 µg), and Myc-tagged PIAS1 mutants 
(NT, PD, SR, CT, FL; 3 µg each). Cell lysates were immunoprecipitated (IP) and 
immunoblotted (IB) with antibodies to Myc and necdin (top two panels). 
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Figure III.3  Necdin interacts with PIAS1 via conserved amino acid stretch on MHD.  
(A) Domain structure of mouse necdin. Abbreviations:MHD, MAGE homology domain; 
ΔH4/5, aa 191-222 deletion.   
(B, C) Interactions of PIAS1 with necdin deletion mutants.  HEK293A cells were 
transfected with expression vectors for Myc-tagged PIAS1 (Myc-PIAS1, 3 µg), 
FLAG-tagged necdin FL (1 µg), CT (1 µg), NT (8 µg) (B); Myc-p53 (3 µg), Myc-PIAS1 (3 
or 6 µg), Necdin FL (1 µg), ΔH4/5 (1 µg) (C).  Immunoprecipitated proteins were 
analyzed using antibodies to Myc (B, C), FLAG (B) and necdin (C)(top two panels).  
Expressed proteins were immunoblotted with antibodies to Myc, necdin, FLAG and 
γ-tubulin (Tub).   
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Figure III.4  Necdin interacts with PIAS1 via a hydrophobic pocket region of MHD. 
 (A, B) Structure models of the necdin H4/5 region.  A structural model of the necdin 
MHD was created by Spanner homology modeling program using the crystal structure 
data of necdin-like 2 (PDB 3NW0).  A view focused on the H4/5 region (necdin aa 
191-222) in the winged-helix B area is presented. Helices 4 (H4) and 5 (H5), positions of 
191(M) and 222 (G) (A), the hydrophobic pocket consisting of surface hydrophobic (red) 
and hydrophilic (blue) residues (B) are indicated.  
(C) Sequence alignment of the H4/5 region.  Consensus amino acid residues (≥3 
identical)(green), the residues unique to necdin-like 2 (red), and Thr (T)(dot) are shown.  
Abbreviations: ND, necdin; A1, MAGEA1; D1, MAGED1; F1, MAGEF1; L2, MAGEL2; 
NL, necdin-like 2.  
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Figure III.5  Necdin inhibits PIAS1-dependent sumoylation of STAT1. 
 (A, B) Inhibition of PIAS1-dependent STAT1 sumoylation by necdin. HEK293A cells 
were transfected with combinations of expression vectors for FLAG-tagged STAT1 
(FLAG-STAT1, 3 µg) (A), HA-tagged SUMO1 (HA-SUMO1, 10 µg), Myc-tagged PIAS1 
(Myc-PIAS1, 3 or 6 µg) and necdin (Necdin, 1 µg). Cell lysates were immunoprecipitated 
(IP) with anti-FLAG antibody (FLAG) and immunoblotted (IB) with anti-HA antibody 
(HA).  Expressed proteins were immunoblotted with antibodies to FLAG, Myc, necdin, 
HA, and γ-tubulin (Tub).  Sumoylated STAT1 signals were quantified by densitometry 
and normalized with STAT1 (second panels) and PIAS1 levels (third panels)(B).  Values 
(B) represent the mean ± SD (n = 3).  **p<0.01.  
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Figure III.6  Necdin inhibits PIAS1-dependent sumoylation of PML. 
 (A, B) Inhibition of PIAS1-dependent PML sumoylation by necdin.  HEK293A cells 
were transfected with combinations of expression vectors for FLAG-tagged PML 
(FLAG-PML, 3 µg), HA-tagged SUMO1 (HA-SUMO1, 4 µg), Myc-tagged PIAS1 
(Myc-PIAS1, 3 or 6 µg) and necdin (Necdin, 1 µg).  PML sumoylation was analyzed 
and quantified as Fig. III.5.  Values (B) represent the mean ± SD (n = 3).  **p<0.01. 
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Figure III.7  Necdin inhibits PIAS1-dependent sumoylation of p53. 
(A) Inhibition of PIAS1-dependent p53 sumoylation by necdin.  HEK293A cells were 
transfected with combinations of expression vectors for FLAG-tagged p53 FLAG-p53, 3 
µg), GFP-tagged SUMO1 (GFP-SUMO1, 4 µg), Myc-tagged PIAS1 (Myc-PIAS1, 3 or 6 
µg) and necdin (Necdin, 1 µg).  Cell lysates were immunoprecipitated (IP) with 
anti-FLAG antibody (FLAG) and immunoblotted (IB) with anti-GFP antibody.  
Expressed proteins were immunoblotted with antibodies to FLAG, Myc, necdin, GFP, 
and γ-tubulin (Tub).   
(B) Analysis of PIAS1-dependent p53 sumoylation by MAGE proteins.  HEK293A 
cells were transfected with combinations of expression vectors for FLAG-tagged 
MAGE(Necdin, MAGE-A1, MAGE-F1 and MAGE-G1), Myc-tagged p53 Myc-p53, 3 
µg), GFP-tagged SUMO1 (GFP-SUMO1, 4 µg), HA-tagged PIAS. p53 sumoylation was 
analyzed as above. 
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Figure III.8  Necdin cancels PIAS1-dependent stimulation of p53 transcriptional 
activity.  
HEK293A cells were transfected with the wwp-luc promoter plasmid and combinations 
of plasmids encoding Flag-tagged p53 (Flag-p53), GFP-tagged SUMO1 (GFP-SUMO1), 
HA-tagged PIAS1 (HA-PIAS1), and necdin. Luciferase activities were measured 24 hrs 
post transfection.  Values represent the mean ± SD (n = 2). 
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Figure III.9  Necdin promotes PIAS1 degradation via the ubiquitin-proteasome 
pathway.  
(A) Necdin-dependent PIAS1 degradation. HEK293A cells were transfected with 
expression vectors for Myc-tagged PIAS1 (Myc-PIAS1, 3 µg) and necdin (0.5, 1, 2 µg).   
(B) Proteasome-mediated degradation of PIAS1. HEK293A cells were transfected with 
expression vectors for Myc-PIAS1 (3 µg) and necdin (1 µg), incubated for 20 hrs, treated 
with 30 µM MG132 (MG132+) or DMSO (MG132-) for 4 hrs, and harvested.  Expression 
of Myc-PIAS1 (Myc), necdin and γ-tubulin (Tub) was analyzed by immunoblotting (A, B).  
(C, D) Necdin-promoted PIAS1 ubiquitination.  HEK293A cells were transfected with 
combinations of expression vectors for FLAG-tagged ubiquitin (FLAG-Ubq, 4 µg)(C), 
Myc-PIAS1 (3 µg), necdin (1 µg) (C).  Transfected cells were incubated for 20 hrs, 
treated with 30 µM MG132 for 4 hrs, and harvested. Cell lysates were immunoprecipitated 
(IP) with anti-Myc antibody (Myc) and immunoblotted (IB) with antibodies to FLAG.  
Expression of Myc-PIAS1 (Myc), necdin, FLAG-tagged proteins (FLAG), and γ-tubulin 
(Tub) was analyzed by immunoblotting. Ubiquitinated PIAS1 levels were determined by 
densitometry of immunoblots (D). Values (B) represent the mean ± SD (n = 3).  
**p<0.01.   
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Figure III.10  Necdin specifically promotes PIAS1 ubiquitination.   
 (A-D) Necdin-promoted PIAS1 ubiquitination.  HEK293A cells were transfected with 
combinations of expression vectors for HA-tagged ubiquitin (HA-Ubq, 8 µg)(A), 
FLAG-tagged ubiquitin (FLAG-Ubq, 4 µg)(C), Myc-PIAS1 (3 µg), FLAG-tagged necdin 
(ND, 2 µg), MAGEA1 (A1, 2 µg), and necdin-like 2 (NL, 1 µg) (A) and FLAG-tagged 
necdin (WT, ND, 2 µg),and necdin∆H4/5(∆H4/5, 5 µg) (C).  Transfected cells were 
incubated for 20 hrs, treated with 30 µM MG132 for 4 hrs, and harvested. Cell lysates were 
immunoprecipitated (IP) with anti-Myc antibody (Myc) and immunoblotted (IB) with 
antibodies to  HA (A) and FLAG (C).  Expression of Myc-PIAS1 (Myc), necdin, 
FLAG-tagged proteins (FLAG), HA-Ubiquitin (HA) and γ-tubulin (Tub) was analyzed by 
immunoblotting. Uquibitinated PIAS1 levels were determined by densitometry of 
immunoblots (B, D). Values represent the mean ± SD (n = 3).  *p<0.05, **p<0.01. 
Abbreviations (A): ND, necdin; A1, MAGEA1; NL, necdin-like 2.   
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Figure III.11  Necdin reduces nuclear PIAS1 levels in transfected cells.   
(A, B) Localization of PIAS1 and necdin in transfected cells. HEK293A cells were 
transfected with expression vectors for Myc-PIAS1 (Myc-PIAS1, 3 µg), necdin (Necdin, 2 
µg) or both (Myc-PIAS1+Necdin) and fixed 24 hrs later (A). Transfected cells were treated 
with 30 µM MG132 for 4 hrs prior to harvest (B). Cells were immunostained with 
antibodies to Myc (top panels) and necdin (middle panels).  Chromosomal DNA (DNA) 
was stained with Hoechst 33342 (bottom panels).  
(C, D) Quantification of PIAS1-expressing cells.  Fluorescence intensities of 
PIAS1-expressing cells cotransfected with necdin were classified into three groups; 
undetectable or barely detectable (±), low (+), and high (++). Arrowheads point to 
representative cells (C).  Classified PIAS1-expressing cells were quantified as % of 
necdin-expressing cells (D). Transfection efficiency (mean ± SD, n = 3): (MG132-) PIAS1, 
24 ± 4%; Necdin, 32 ± 5%; PIAS1+Necdin, 32 ± 5%; (MG132+) PIAS1, 27 ± 1%; Necdin, 
33 ± 3%; PIAS1+Necdin, 39 ± 4%. Values (D) represent the mean ± SD (n = 3). *p<0.05.  
Scale bars (A-C), 20 µm.   
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Figure III.12  PIAS1 terminal-truncated mutants interact with necdin. 
 (A) Diagrams of PIAS1 terminal-truncated mutants.  Abbreviations: FL, full-length; 
ΔNT, N-terminal deletion mutant; ΔCT, C-terminal deletion mutant. PIAS domain names 
are as in Fig. III.2A.  
(B) Interactions of necdin with PIAS1 mutants. HEK293A cells were transfected with 
expression vectors for necdin (1 µg), Myc-tagged PIAS1 FL (6 µg), ΔNT (4 µg) and ΔCT 
(8 µg). Cell lysates were immunoprecipitated (IP) with anti-necdin antibody and 
immunoblotted (IB) with anti-Myc antibody.  Expression levels of Myc-PIAS1 mutants 
(Myc), necdin (Necdin), FLAG-ubiquitin (FLAG) and γ-tubulin (Tub) were analyzed by 
immunoblotting . 
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Figure III.13 PIAS1 terminal-truncated mutants lack necdin-dependent 
ubiquitination.  
(A, B) Protein levels of PIAS1 terminal-truncated mutants. HEK293A cells were 
transfected with expression vectors for Myc-tagged PIAS1 mutants (FL, ΔNT, ΔCT; 3 µg 
each) and necdin (1 µg)(A). Expression levels of Myc-PIAS1 mutants (Myc) were 
quantitated (B).  Values represent the mean ± SD (n = 3).  ***p<0.001. 
(C) Ubiquitination of PIAS1 terminal-truncated mutants.  HEK293A cells were 
transfected with expression vectors for FLAG-tagged ubiquitin (FLAG-Ubq, 4 µg), 
Myc-tagged PIAS1 mutants (3 µg), and necdin (1 µg), cultured for 20 hrs, and treated with 
30 µM MG132 for 4 hrs prior to harvest.  Cell lysates were immunoprecipitated (IP) with 
anti-Myc antibody (Myc) and immunoblotted (IB) with anti-FLAG antibody.  Expression 
levels of Myc-PIAS1 mutants (Myc), necdin (Necdin), FLAG-ubiquitin (FLAG) and 
γ-tubulin (Tub) were analyzed by immunoblotting. 
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Figure III.14  Subcellular localization of PIAS1-truncated mutants.  
(A) Subcellular localization of necdin and PIAS1 terminal-truncated mutants. HEK293A 
cells were transfected with expression vectors for necdin (2 µg), Myc-tagged full-length 
PIAS1 and truncated mutants (FL, ΔNT, ΔCT; 3 µg each), fixed 24 hrs later, and 
immunostained with antibodies to necdin and Myc (top panels).  Chromosomal DNA 
(DNA) was stained with Hoechst 33342 for nuclear location (middle panels).  Images of 
expressed proteins and nuclear DNA are merged (bottom panels).  Transfection 
efficiency (mean ± SD, n = 3): Necdin, 20 ± 3%; FL,15 ± 4%; ΔNT, 17 ± 3%; ΔCT, 7 ± 
8%.  
(B) HEK293A cells were transfected with expression vectors for Myc-tagged full-length 
PIAS1 (Myc-PIAS1, 3 µg) and N-terminal-truncated PIAS1 mutant (PIAS1ΔNT, 3 µg), 
fixed 24 hrs later, and double-stained for Myc-PIAS1 (Myc) and PML. Images of Myc 
and PML are merged (Merge).  Arrows point to Myc-PIAS1+/PML+ speckles.  
Chromosomal DNA (DNA) was stained with Hoechst 33342. Scale bar, 10 µm.   
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Figure III.15  PIAS1 terminal-truncated mutants dissociate from the nuclear matrix. 
Localization of necdin and PIAS1 terminal-truncated mutants in the nuclear matrix.  The 
nuclear matrix of HEK293 cells was prepared 24 hrs after transfection.  Proteins associated 
with the nuclear matrix were double-stained for necdin (or Myc)(top panels) and the nuclear 
matrix protein NuMA (middle panels), and their images are merged (bottom panels). Scale 
bars 20 µm.   
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Figure III.16  Lentivirus- mediated expression of necdin reduces endogenous PIAS1 
levels.  
(A-C) H1299 cells infected with lentiviruses.  Lentivirus vectors for EmGFP and necdin 
(+EmGFP) were infected into H1299 cells. Infected cells were grown on coverslips and 
fixed for immunocytochemistry using antibodies to GFP and necdin. Chromosomal DNA 
(DNA) was stained with Hoechst 33342.  Scale bar, 20 µm.  (B) Western blot analysis. 
Cell lysates of uninfected (Virus-, Plate Nos. 1-3) and infected cells expressing EmGFP 
(EmGFP, Plate Nos. 4-6) and necdin (Necdin, Plate Nos. 7-9) were analyzed 72 hrs after 
infection by immunoblotting using antibodies to PIAS1, necdin and γ-tubulin (Tub).  (C) 
Quantification of the PIAS1 protein levels.  Signal intensities of PIAS1 and γ-tubulin 
were quantitated by densitometry, and PIAS1 values were normalized with those of 
γ-tubulin.   
(D,E) Effect of necdin on H1299 proliferation.  Proliferation of lentivirus-infected H1299 
cells was determined by BrdU incorporation assay. Infected cells were stained for BrdU 
incorporated into nuclear DNA (A), and BrdU-positive cells were counted after 
counterstaining with Hoechst 33342 (B). Values represent the mean ± SD (n = 3). *p<0.05, 
**p<0.03. 
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IV.  DISCUSSION 
IV-1. Characterization of MAGE proteins with different responses to 
SUMO E3 ligases  
 The present study has demonstrated that necdin interacts with PIAS1 SUMO E3 
ligase and suppresses its catalytic activity.  Other MAGE proteins, except necdin-like 
2, also bound to PIAS1, whereas Nsmce2 and Cbx4 SUMO E3 ligases bound only to 
MAGEA1.  Necdin interacts with RanBP2, another well-studied SUMO E3 ligase 
associated with the nuclear pore complex (K Fujiwara and K Yoshikawa, unpublished 
observations).  Several MAGE proteins bind to RING-type ubiquitin E3 ligases such 
as TRIM27 and TRIM28 to promote ubiquitination of their substrates, but necdin is 
unable to interact with these ubiquitin E3 ligases (Doyle et al., 2010; Yang et al., 2007).  
We confirmed the previous findings (Doyle et al., 2010; Taylor et al., 2008) that 
Nsmce1, the ubiquitin E3 ligase in the SMC5/6 complex, interacts with necdin-like 2 
and MAGEF1 but not with necdin.  Necdin-like 2 shows biochemical and functional 
characteristics similar to those of necdin (Kuwako et al., 2004). Additionally, chicken 
and Drosophila MAGE proteins, which resemble mammalian necdin-like 2, exhibit 
functional similarities to necdin (Lopez-Sanchez et al., 2007; Nishimura et al., 2008).  
In contrast to these similarities among MAGE family proteins, it is likely that 
mammalian MAGE proteins are diversified to interact with their specific ubiquitin and 
SUMO E3 ligases (Fig. IV.1).   
 
IV-2. Necdin-dependent ubiquitin-proteasomal degradation of PIAS1  
The present study has also shown that necdin promotes degradation of PIAS1 via 
the ubiquitin-proteasome pathway.  Necdin is likely to enhance PIAS1 ubiquitination 
by interacting with endogenous ubiquitin E3 ligases.  PIAS1 is ubiquitinated by the 
ubiquitin E3 ligase hSiah2 (human homologues of seven in absentia) (Depaux et al., 
2007). Necdin binds to the ubiquitin E3 ligase Mdm2 and promotes degradation of the 
proapoptotic protein CCAR1/CARP1 (cell cycle apoptosis regulatory protein) (Francois 
et al., 2012). Thus, we examined whether hSiah2 and Mdm2 mediate necdin-promoted 
PIAS1 ubiquitination.  However, we found that these ubiquitin E3 ligases were unable 
to ubiquitinate PIAS1 in a necdin-dependent manner (Gur and Yoshikawa, unpublished 
observations). Although detailed molecular mechanisms underlying necdin-promoted 
PIAS1 ubiquitination remain to be elucidated, we assume that necdin, like other MAGE 
proteins (Doyle et al., 2010), serves as an adaptor to form a necdin-ubiquitin E3 ligase 
complex for PIAS1 ubiquitination.  We found that PIAS1 promoted PML 
SUMOylation, consistent with the previous report (Rabellino et al., 2012).  
PIAS1-dependent PML SUMOylation may promote PML degradation by RNF4, a 
SUMO-directed E3 ubiquitin ligase (Lallemand-Breitenbach et al., 2008; Rabellino et 
al., 2012; Tatham et al., 2008).  Thus, it is possible that necdin prevents PML 
degradation by suppressing PIAS1-dependent PML SUMOylation.  Because PML 
regulates cell fate during neocortical development (Regad et al., 2009), we speculate 
that necdin stabilizes PML by suppressing endogenous PIAS1 during neuronal 
differentiation. 
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IV-3. Molecular mechanisms of ubiquitin-proteasomal degradation of 
PIAS1  
The necdin-interacting region of PIAS1 consists of two known domains: the 
PINIT domain that contains the Pro-Ile-Asn-Ile-Thr motif in the middle of the 
PIAS-conserved sequence stretch (Duval et al., 2003) and the SP-RING domain similar 
to the RING-finger domain found in many ubiquitin E3 ligases (Hochstrasser, 2001; 
Shuai and Liu, 2005).  These two domains are highly conserved among PIAS family 
members (Rytinki et al., 2009).  Although PIAS1 interacts with SUMO-modified 
substrates via its distinct regions throughout the whole molecule (Shuai and Liu, 2005), 
the SUMO ligase activity relies solely on these central domains (Liang et al., 2004).  
As expected, necdin inhibited PIAS1-dependent SUMOylation of STAT1 (Liu et al., 
1998) and PML (Rabellino et al., 2012).  Thus, it is likely that necdin-mediated 
suppression of the PIAS1 catalytic activity is attributed to its specific binding region in 
PIAS1. 
 The N-terminal deletion of PIAS1 lost both ubiquitination and responsiveness to 
necdin.  The N-terminal domain contains a highly conserved SAP domain that 
mediates association with the nuclear matrix.  Thus, PIAS1 is likely to interact with 
the nuclear matrix via the SAP domain.  We found that the PIAS1 N-terminal deletion 
mutant was dissociated from the nuclear matrix and translocated to the PML bodies, 
consistent with the previous report (Sudharsan and Azuma, 2012).  We have 
previously shown that necdin localizes in the nuclear matrix and interacts with the 
nuclear matrix-associated protein SAF-A/hnRNP U (Taniura and Yoshikawa, 2002).  
These findings suggest that necdin and PIAS1 are colocalized in the nuclear matrix, 
where necdin modulates PIAS1 ubiquitination.  Intriguingly, PIAS1 C-terminal 
deletion enhanced ubiquitination in a necdin-independent manner, implying that the 
PIAS1 C-terminus negatively controls necdin-promoted ubiquitination.  Because 
C-terminally truncated PIAS1 was translocated to the cytoplasm, the C-terminus of 
PIAS1 is likely to contribute to the nuclear retention.  We speculate that these terminal 
regions are required for the translocation of PIAS1 to the nuclear matrix that contributes 
to the necdin-dependent ubiquitination (Fig. IV.2).  
 
IV-4. Physiological roles of necdin-induced regulation of PIAS1 
Necdin plays anti-apoptotic and pro-survival roles in various cell types such as 
neurons and neural stem/progenitor cells through interactions with various proteins 
(Hasegawa and Yoshikawa, 2008; Huang et al., 2013; Kobayashi et al., 2002; Kurita et 
al., 2006; Kuwako et al., 2005; Minamide et al., 2014; Takazaki et al., 2002; Taniura et 
al., 1999).  Previous studies have shown that PIAS1 promotes apoptosis in response to 
various stimuli (Liu and Shuai, 2001; Sudharsan and Azuma, 2012; Yang et al., 2013).  
These observations suggest that necdin targets PIAS1 to suppress its proapoptotic 
activities.  Because the necdin-binding region in PIAS1 is highly conserved among 
PIAS family members, it is possible that necdin also interacts with other PIAS family 
proteins to regulate their functions.  Although information on the regulation of PIAS 
family proteins during neuronal development is currently limited, we speculate that 
necdin interacts with PIAS family proteins to modulate SUMOylation of their target 
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proteins involved in mammalian neuron development.   
 Necdin is expressed abundantly in terminally differentiated neurons, whereas its 
protein levels are reduced in undifferentiated neural stem/progenitor cells (Huang et al., 
2013). SUMOylation plays key regulatory roles in the course of embryonic 
development.   
Ubc9-/- knockout mice exhibit embryonic lethal phenotype, indicating that 
SUMOylation is essential for embryonic development. Embryonic stem cells derived 
from the inner cell mass of Ubc9-/- mice display severe apoptosis and fail to proliferate. 
Furthermore, nuclear organization and molecular events concerning cell division, such 
as chromosomal segregation, is aberrant in embryonic cells derived from Ubc9-/- mice 
(Nacerddine et al., 2005).  These results imply that SUMOylation plays a key role in 
the maintenance of stem/progenitor cells in the undifferentiated state.  
SUMO-conjugated proteins are abundant in neural stem cells at early stages of brain 
development but their levels decrease during neural differentiation (our unpublished 
observations).  Collectively, our results shed light onto the molecular mechanism 
underlying necdin-mediated SUMOylation and its involvement in the control of 
neuronal differentiation.  
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IV-5. Figures IV.1, 2    
 
 
Figure IV.1  Differential binding of MAGE proteins to SUMO and ubiquitin E3 
ligases.  
 
Figure IV.2  Necdin-mediated effects on PIAS1 are dependent on subcellular 
localization.   
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Figure IV.1  Differential binding of MAGE proteins to SUMO and ubiquitin E3 
ligases.  The interactions between MAGE proteins and SUMO E3 ligases are 
schematically presented (upper panel).  Information on the interactions between 
MAGE proteins and ubiquitin E3 ligases was taken from the report by Doyle et al. 
(2010)(lower panel). Abbreviations: ND, necdin; A1, MAGEA1; D1, MAGED1; F1, 
MAGEF1; NL, necdin-like 2; L2, MAGEL2; A2/3/6, MAGEA2/MAGEA3/MAGEA6. 
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Figure IV.2  Necdin-mediated effects on PIAS1 are dependent on subcellular 
localization.  For details, see Discussion. 
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